Mirum Pharmaceuticals (NASDAQ:MIRM) Upgraded by Royal Bank Of Canada to “Moderate Buy” Rating

Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by equities researchers at Royal Bank Of Canada to a “moderate buy” rating in a report released on Tuesday,Zacks.com reports.

Several other research firms have also commented on MIRM. Leerink Partners set a $100.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Stifel Nicolaus raised their price objective on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Finally, Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.17.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $105.10 on Tuesday. The stock has a market cap of $5.40 billion, a price-to-earnings ratio of -122.21 and a beta of 0.49. The stock’s 50 day simple moving average is $88.64 and its two-hundred day simple moving average is $77.02. Mirum Pharmaceuticals has a fifty-two week low of $36.88 and a fifty-two week high of $107.41. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 9,108 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $940,856.40. Following the completion of the sale, the chief executive officer directly owned 160,294 shares in the company, valued at $16,558,370.20. The trade was a 5.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Eric Bjerkholt sold 1,053 shares of the company’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $101,288.07. Following the sale, the chief financial officer directly owned 43,741 shares of the company’s stock, valued at $4,207,446.79. The trade was a 2.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,136 shares of company stock valued at $4,352,029 over the last ninety days. 14.36% of the stock is owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CWM LLC raised its position in Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after acquiring an additional 161 shares during the period. Legal & General Group Plc increased its stake in shares of Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock worth $2,189,000 after purchasing an additional 176 shares in the last quarter. MCF Advisors LLC raised its holdings in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares during the period. Janney Montgomery Scott LLC lifted its position in Mirum Pharmaceuticals by 6.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock valued at $253,000 after purchasing an additional 200 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its position in Mirum Pharmaceuticals by 2.2% during the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after purchasing an additional 215 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.